Clinic
Ascension ST Francis Hospital, INC
Ascension ST Francis Hospital, INC was paid $35.87M by Medicaid between Jan 2018 and Dec 2024, across 340 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoASCENSION ST FRANCIS HOSPITAL, INC
MILWAUKEE, WI 53215
MILWAUKEE, WI 53215
33aNPI1225087190assigned 05/09/2006
33bProvider typeInfusion Therapy Clinic/Center
28Total paid$35.87M
24GClaims1,212,088
24DCodes billed340
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCULLOUGH, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 185,070 | $5.58M | |
| 2019 | 189,599 | $5.66M | |
| 2020 | 143,738 | $4.45M | |
| 2021 | 188,425 | $5.26M | |
| 2022 | 172,300 | $5.42M | |
| 2023 | 196,672 | $5.42M | |
| 2024incomplete | 136,284 | $4.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 73,856 | 66,201 | $4.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.7% | 55,155 | 48,849 | $3.12M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.4% | 20,427 | 17,063 | $3.02M |
| J2350 | Injection, ocrelizumab, 1 mg | 5.2% | 475 | 418 | $1.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 27,419 | 23,883 | $1.46M |
| 80053 | Comprehensive metabolic panel | 3.7% | 52,827 | 44,604 | $1.32M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.9% | 10,600 | 9,831 | $1.04M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 26,183 | 7,809 | $930K |
| J2323 | Injection, natalizumab, 1 mg | 2.2% | 2,192 | 1,980 | $786K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.2% | 11,904 | 11,015 | $771K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 10,861 | 10,184 | $722K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 14,892 | 13,702 | $702K |
328 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 6,507 | $550K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 5,398 | $539K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 19,037 | $470K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 6,277 | $454K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 7,184 | $445K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 8,347 | $439K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 65,143 | $433K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 2,535 | $422K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 5,775 | $413K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 8,379 | $401K |
| 81001 | 1.1% | 28,511 | $385K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 5,302 | $383K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 15,943 | $357K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,446 | $313K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,287 | $309K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,190 | $292K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,291 | $282K |
| 87081 | <1% | 9,890 | $259K | |
| 81025 | <1% | 26,034 | $245K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,991 | $236K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 6,617 | $210K |
| G0378 | Hospital observation service, per hour | <1% | 5,404 | $207K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,018 | $205K |
| 82962 | <1% | 14,091 | $204K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,691 | $191K |
| 81003 | <1% | 17,509 | $185K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,855 | $169K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,871 | $161K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,933 | $143K |
| 87634 | <1% | 2,285 | $139K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,704 | $139K |
| 80061 | Lipid panel | <1% | 9,638 | $137K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,943 | $122K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,892 | $122K |
| 84484 | <1% | 13,473 | $122K | |
| 12001 | <1% | 1,399 | $121K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 551 | $115K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,793 | $114K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,445 | $112K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,019 | $111K |
| 84702 | <1% | 4,117 | $108K | |
| 86481 | <1% | 1,308 | $101K | |
| 59025 | Fetal non-stress test | <1% | 572 | $100K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 693 | $98K |
| 76830 | Ultrasound, transvaginal | <1% | 2,352 | $97K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,470 | $95K |
| 83690 | <1% | 15,782 | $94K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,068 | $91K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 24,821 | $90K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,504 | $87K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,560 | $86K |
| 80143 | <1% | 3,449 | $86K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,862 | $85K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,242 | $84K |
| 96415 | <1% | 1,137 | $83K | |
| 93798 | <1% | 653 | $82K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,049 | $81K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,723 | $81K |
| 96367 | <1% | 1,681 | $76K | |
| 97161 | <1% | 2,078 | $75K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,095 | $71K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,825 | $68K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 756 | $67K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,381 | $66K |
| 76642 | <1% | 1,772 | $66K | |
| 82607 | <1% | 4,289 | $64K | |
| 97162 | <1% | 1,747 | $63K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 483 | $60K |
| 95886 | <1% | 782 | $60K | |
| 12011 | <1% | 603 | $58K | |
| 83880 | <1% | 2,630 | $57K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,764 | $56K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,178 | $54K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 379 | $52K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 733 | $51K |
| 80074 | <1% | 1,615 | $50K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 248 | $49K |
| 85027 | <1% | 9,376 | $46K | |
| 82728 | <1% | 2,018 | $46K | |
| 76801 | <1% | 1,463 | $45K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,935 | $44K |
| 81511 | <1% | 229 | $41K | |
| 72100 | <1% | 3,298 | $39K | |
| 10060 | <1% | 504 | $39K | |
| 82950 | <1% | 530 | $38K | |
| 93971 | <1% | 1,326 | $38K | |
| 80179 | <1% | 3,412 | $36K | |
| 95811 | <1% | 170 | $35K | |
| 83605 | <1% | 3,675 | $33K | |
| 83735 | <1% | 6,701 | $33K | |
| 54161 | <1% | 45 | $32K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 565 | $32K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 735 | $31K |
| 86480 | <1% | 488 | $31K | |
| 85610 | <1% | 7,042 | $30K | |
| 12002 | <1% | 387 | $30K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 526 | $30K |
| 93458 | <1% | 66 | $29K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,542 | $28K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 412 | $27K |
| 77066 | Tomosynthesis, mammo | <1% | 1,085 | $27K |
| 94060 | <1% | 1,203 | $27K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,938 | $26K |
| 84439 | <1% | 2,678 | $26K | |
| 84703 | <1% | 2,908 | $26K | |
| 86780 | <1% | 2,254 | $25K | |
| 87186 | <1% | 3,378 | $25K | |
| 86850 | <1% | 2,805 | $25K | |
| 87077 | <1% | 2,303 | $24K | |
| 87040 | <1% | 1,730 | $23K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 312 | $23K |
| 70486 | <1% | 627 | $21K | |
| 85379 | <1% | 2,568 | $21K | |
| 82247 | <1% | 297 | $21K | |
| 73564 | <1% | 3,588 | $20K | |
| 82565 | <1% | 1,864 | $20K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,065 | $19K |
| 80076 | <1% | 2,317 | $19K | |
| 87147 | <1% | 3,287 | $19K | |
| 93017 | <1% | 529 | $19K | |
| 87340 | <1% | 1,939 | $19K | |
| 73030 | <1% | 3,002 | $18K | |
| 95806 | <1% | 354 | $18K | |
| 86360 | <1% | 638 | $18K | |
| 74018 | <1% | 2,293 | $18K | |
| 82784 | <1% | 1,119 | $18K | |
| 90715 | <1% | 2,502 | $17K | |
| 73630 | <1% | 4,137 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 17,908 | $16K |
| 86900 | <1% | 3,224 | $16K | |
| 87015 | <1% | 316 | $15K | |
| 86355 | <1% | 654 | $15K | |
| 73130 | <1% | 3,291 | $15K | |
| 94729 | <1% | 855 | $15K | |
| 97116 | <1% | 741 | $15K | |
| 85007 | <1% | 4,993 | $15K | |
| 86762 | <1% | 926 | $14K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 285 | $14K |
| 86901 | <1% | 4,049 | $13K | |
| 82077 | <1% | 822 | $13K | |
| 85730 | <1% | 2,946 | $13K | |
| 72040 | <1% | 832 | $13K | |
| 87070 | <1% | 948 | $13K | |
| 97165 | <1% | 379 | $13K | |
| 70498 | <1% | 150 | $13K | |
| 29125 | <1% | 339 | $13K | |
| 86704 | <1% | 1,275 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,909 | $12K |
| 71250 | <1% | 398 | $12K | |
| 36514 | <1% | 99 | $12K | |
| 82550 | <1% | 2,233 | $11K | |
| 83540 | <1% | 1,857 | $11K | |
| 73610 | <1% | 3,325 | $11K | |
| 83655 | <1% | 735 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,996 | $11K |
| 83550 | <1% | 1,533 | $11K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 215 | $11K |
| 77062 | <1% | 699 | $10K | |
| 86140 | <1% | 1,842 | $10K | |
| 73502 | <1% | 1,382 | $10K | |
| 87210 | <1% | 1,785 | $10K | |
| 77065 | Tomosynthesis, mammo | <1% | 485 | $10K |
| 82043 | <1% | 1,825 | $9K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 150 | $9K |
| 70496 | <1% | 103 | $9K | |
| 86803 | <1% | 763 | $9K | |
| 90837 | Psychotherapy session, about an hour | <1% | 274 | $9K |
| 0002A | <1% | 623 | $8K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 213 | $8K |
| 83970 | <1% | 277 | $8K | |
| 64615 | <1% | 155 | $8K | |
| 0001A | <1% | 625 | $8K | |
| 72141 | <1% | 142 | $7K | |
| 82746 | <1% | 722 | $7K | |
| 82570 | <1% | 1,265 | $7K | |
| 82800 | <1% | 828 | $7K | |
| 87088 | <1% | 898 | $7K | |
| 73110 | <1% | 1,896 | $6K | |
| 64644 | <1% | 108 | $6K | |
| 86703 | <1% | 389 | $6K | |
| 87207 | <1% | 299 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 79 | $5K |
| 84153 | <1% | 325 | $5K | |
| 85652 | <1% | 1,616 | $5K | |
| 86711 | <1% | 567 | $5K | |
| 82553 | <1% | 1,130 | $5K | |
| 83525 | <1% | 440 | $5K | |
| 43248 | <1% | 25 | $4K | |
| 84132 | <1% | 1,668 | $4K | |
| 72070 | <1% | 467 | $4K | |
| 87205 | <1% | 974 | $4K | |
| 84100 | <1% | 1,303 | $4K | |
| 86706 | <1% | 342 | $4K | |
| 82010 | <1% | 619 | $4K | |
| 95874 | <1% | 595 | $4K | |
| 86359 | <1% | 159 | $4K | |
| 84450 | <1% | 663 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 30 | $4K |
| 84460 | <1% | 666 | $4K | |
| 70491 | <1% | 43 | $4K | |
| 87075 | <1% | 523 | $4K | |
| 84481 | <1% | 274 | $4K | |
| 93356 | <1% | 34 | $3K | |
| 84550 | <1% | 682 | $3K | |
| 76770 | <1% | 91 | $3K | |
| 97602 | <1% | 179 | $3K | |
| 86705 | <1% | 218 | $3K | |
| 73080 | <1% | 767 | $3K | |
| 76942 | <1% | 741 | $3K | |
| 73140 | <1% | 1,351 | $3K | |
| 97035 | <1% | 228 | $3K | |
| 81510 | <1% | 21 | $2K | |
| 87631 | <1% | 23 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,917 | $2K |
| 95911 | <1% | 42 | $2K | |
| 73562 | <1% | 248 | $2K | |
| 82947 | <1% | 260 | $2K | |
| 82105 | <1% | 30 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 58 | $2K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 54 | $2K |
| 82248 | <1% | 419 | $2K | |
| 77080 | <1% | 25 | $2K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 102 | $2K |
| 76870 | <1% | 42 | $1K | |
| 36591 | <1% | 653 | $1K | |
| 76536 | <1% | 31 | $1K | |
| J0583 | Injection, bivalirudin, 1 mg | <1% | 12 | $1K |
| 71101 | <1% | 965 | $1K | |
| 94726 | <1% | 347 | $1K | |
| 95819 | <1% | 27 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 173 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 80 | $1K |
| 83516 | <1% | 66 | $1K | |
| 10061 | <1% | 12 | $930.69 | |
| 80164 | <1% | 69 | $906.69 | |
| 91300 | <1% | 268 | $905.92 | |
| 83615 | <1% | 236 | $873.24 | |
| 73590 | <1% | 360 | $848.15 | |
| 94150 | <1% | 1,419 | $801.71 | |
| 82040 | <1% | 71 | $784.97 | |
| 72110 | <1% | 61 | $691.96 | |
| 73090 | <1% | 434 | $683.45 | |
| 77061 | <1% | 56 | $671.91 | |
| 88738 | <1% | 65 | $670.66 | |
| 80050 | General health panel | <1% | 129 | $646.10 |
| Q3014 | Telehealth originating site facility fee | <1% | 332 | $641.46 |
| 86038 | <1% | 66 | $626.23 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,588 | $612.70 |
| 80305 | <1% | 55 | $603.08 | |
| 86787 | <1% | 101 | $507.67 | |
| 73560 | <1% | 26 | $495.08 | |
| 94727 | <1% | 214 | $465.82 | |
| 87522 | Neg quan hep c or qual rna | <1% | 15 | $445.36 |
| 82951 | <1% | 14 | $415.08 | |
| 90674 | <1% | 37 | $403.25 | |
| 82378 | <1% | 28 | $354.30 | |
| 94762 | <1% | 33 | $349.73 | |
| 73660 | <1% | 13 | $343.32 | |
| 85018 | <1% | 16 | $318.60 | |
| 74019 | <1% | 564 | $318.49 | |
| 88342 | <1% | 689 | $269.95 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,318 | $267.34 |
| 84155 | <1% | 169 | $241.98 | |
| 64643 | <1% | 26 | $166.80 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,175 | $163.81 |
| 85049 | <1% | 67 | $156.54 | |
| 86039 | <1% | 14 | $131.52 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,445 | $126.34 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,472 | $108.68 |
| J2704 | Injection, propofol, 10 mg | <1% | 8,421 | $91.81 |
| G0008 | Administration of influenza virus vaccine | <1% | 63 | $63.66 |
| 84156 | <1% | 15 | $58.12 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 195 | $55.99 |
| 88304 | <1% | 457 | $48.04 | |
| 99152 | <1% | 550 | $38.08 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,795 | $35.65 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,107 | $27.72 |
| 96376 | <1% | 3,199 | $24.39 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,110 | $24.31 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,477 | $23.33 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,838 | $22.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,160 | $20.57 |
| 99153 | Mod sedat endo service >5yrs | <1% | 420 | $19.03 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,001 | $18.41 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,234 | $18.30 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,560 | $14.96 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,320 | $11.51 |
| A9270 | Non-covered item or service | <1% | 13,323 | $6.69 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 91 | $6.60 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,333 | $6.05 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,615 | $5.98 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 965 | $5.93 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,231 | $4.96 |
| 94760 | <1% | 1,426 | $4.23 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,267 | $1.09 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 609 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,294 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 47 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 291 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 79 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 33 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 123 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 26 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 177 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 20 | $0.00 |
| 88312 | 0% | 105 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 92 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 25 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 45 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 36 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 13 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 332 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 696 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 234 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 16 | $0.00 |
| C1769 | Guide wire | 0% | 728 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 161 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 237 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 17 | $0.00 |
| J3490 | Unclassified drugs | 0% | 13 | $0.00 |
| 74021 | 0% | 25 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 25 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 50 | $0.00 |
| 99292 | 0% | 193 | $0.00 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 36 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 40 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 96 | $0.00 |
| 73552 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCULLOUGH, MICHAEL (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.